Compare DexCom, Inc. (DXCM) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Altria Group Inc — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Altria Group Inc trades at $71.28 (market cap $119.25B). The key difference: Altria Group Inc is far larger — about 3.7× DexCom, Inc.'s market cap, and Altria Group Inc pays a 6.22% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Altria Group Inc for 154 Days on average.
| DXCM | MO | |
|---|---|---|
Market Cap | $31.86B | $119.25B |
Volume | 3,607,070 | 11,178,169 |
Sector | Health | Consumer Staples |
52-Week High | $92.34 | $74.92 |
52-Week Low | $54.84 | $54.72 |
Typical Hold Time | 62 Days | 154 Days |
Enterprise Value | $31.32B | $141.46B |
Dividend Yield | — | 6.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Altria Group (MO) trades at $69.39, up 1.22% today, near the analyst consensus price target of $69.71. The stock shows a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company maintains robust profitability with a 39% net income margin and strong cash flow, though revenue has been slightly declining. Recent earnings have been mixed, with one beat and two misses in the last three quarters. A high dividend yield of approximately 6.6% is supported by 60 consecutive annual increases, but the balance sheet shows negative shareholder equity.
The outlook for MO balances income appeal against structural challenges. The high dividend and bullish analyst consensus (61.5% buy ratings) offer value for income investors, but risks include declining core tobacco sales, regulatory pressures on nicotine products, and a leveraged balance sheet. Earnings growth and smoke-free product adoption are critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
